Shopping Cart 0
Cart Subtotal
USD 0

AdAlta Ltd (1AD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

AdAlta Ltd (AdAlta), formerly AdAlta Pty Ltd, is a biotechnology company that discovers and develops new class of protein therapeutics for wide range of human diseases. The company's lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its i-body products are developed using proprietary technology platform that delivers specific biologics and affinity against a variety of therapeutic and diagnostic targets such as cell surface, membrane spanning and complex proteins. AdAlta utilizes the i-body technology to create a pipeline of new drugs for treating fibrotic diseases. The company collaborates with various pharmaceutical and biotech companies in Australia. AdAlta is headquartered in Melbourne, Victoria, Australia.

AdAlta Ltd (1AD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AdAlta Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

AdAlta Expands Collaboration with The Alfred Hospital 11

AdAlta Enters into Agreement with XL-protein 12

Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13

Licensing Agreements 14

Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14

Equity Offering 15

AdAlta to Raise Funds through Share Purchase Plan 15

AdAlta Raises USD3.1 Million in Private Placement of Shares 16

AdAlta Raises USD7.5 Million in IPO 17

AdAlta Ltd-Key Competitors 18

AdAlta Ltd-Key Employees 19

AdAlta Ltd-Locations And Subsidiaries 20

Head Office 20

Recent Developments 21

Financial Announcements 21

Feb 20, 2018: AdAlta: Half year report for the half-year ended 31 December 2017 21

Apr 26, 2017: AdAlta Announces Quarterly Cash Flow Statement 23

Jan 31, 2017: AdAlta: Quarterly Cash Flow Statement 25

Government and Public Interest 27

Jul 25, 2018: AdAlta's i-body platform: reaching for the high-hanging fruit 27

Jul 24, 2017: AdAlta and La Trobe awarded SIEF Business Fellowship grant to identify novel i-bodies 28

Product News 29

12/07/2017: NHMRC USD 768,000 Grant for Development of AD-114 in Chronic Kidney Disease 29

11/13/2017: AdAlta to present at Anti-Fibrotic Drug Development Summit in Boston 30

08/21/2017: Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers 31

05/08/2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 32

05/01/2017: AdAlta releases Idiopathic Pulmonary Fibrosis Overview Document 33

01/16/2018: Researcher looks to next generation antibody treatment for Chronic Kidney Disease 34

01/08/2018: AdAlta to present at the Biotech Showcase in San Francisco 35

Product Approvals 36

Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease 36

Clinical Trials 37

Apr 18, 2018: AdAlta to advance improved lung fibrosis therapy, AD-214 37

Nov 22, 2017: AdAlta gets commercial-ready after pre-clinical safety studies show promising results 38

Sep 19, 2017: AdAlta announces additional, positive safety data of AD-114 in non-human primates 39

Sep 04, 2017: AdAlta to present kidney fibrosis data at Australian and New Zealand Society of Nephrology Annual Scientific Meeting 40

Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 41

Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential 43

Other Significant Developments 44

Oct 17, 2018: AdAlta: Quarterly cash flow statement 44

Jul 16, 2018: AdAlta: Quarterly Cash Flow Statement Quarter ended 30 June 2018 46

Jul 27, 2017: AdAlta: Announces Quarterly Cash Flow Statement 47

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

AdAlta Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AdAlta Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AdAlta Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

AdAlta Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AdAlta Expands Collaboration with The Alfred Hospital 11

AdAlta Enters into Agreement with XL-protein 12

Crossbeta Biosciences Enters Into Agreement With AdAlta For Drug Discovery 13

Crossbeta Biosciences Enters into Licensing Agreement with AdAlta 14

AdAlta to Raise Funds through Share Purchase Plan 15

AdAlta Raises USD3.1 Million in Private Placement of Shares 16

AdAlta Raises USD7.5 Million in IPO 17

AdAlta Ltd, Key Competitors 18

AdAlta Ltd, Key Employees 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

AdAlta Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.